药物耐药性在晚发性中
Chen Buxbaum1, Mark Katson1, Moshe Herskovitz2
1Department of Neurology, Rambam Health Care Campus, Haifa, Israel.
The Israel Medical Association journal : IMAJ
|June 29, 2023
概括
在50岁以上的患者中,晚发性通常可以用单一药物治疗. 在这个人群中,耐药性的发病率很低,并且保持稳定.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 发病率随着年龄的增长而上升,严重影响到老年人.
- 晚发性与早发性相比,具有独特的特征.
研究的目的:
- 为了评估50岁及以上患者的治疗反应.
- 在这个人口群体中评估耐药 (DRE) 的患病率.
主要方法:
- 对50岁以上发作患者的回顾性研究.
- 纳入标准:发病≥50年,随访≥1年,没有快速进展的疾病.
主要成果:
- 最初,15.7%的患者患有DRE,主要是单一治疗.
- 平均随访时间为2.8年后,12.2%的人患有DRE.
结论:
- 晚发性 (发病年龄大于50岁) 通常对单一治疗有反应.
- 老年人中耐药性的比例相对较低且稳定.
相关概念视频
Epilepsy and Seizures: Overview
228
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
228
Antiepileptic Drugs: Potassium Channel Activators
217
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
217
Antiepileptic Drugs: Glutamate Antagonists
429
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
429
Antiepileptic Drugs: GABAergic Pathway Potentiators
467
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
467
Antiepileptic Drugs: Sodium Channel Blockers
690
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
690
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
351
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
351


